Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21)

doi:10.1186/s12874-023-01944-2

. 2023 May 25;23(1):129.

doi: 10.1186/s12874-023-01944-2.

Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21^st century (GIVES-21)

Joyce W Y Mak¹, Yang Sun², Julajak Limsrivilai³, Murdani Abdullah⁴, Jamilya Kaibullayeva⁵, Domingo Balderramo⁶, Beatriz Iade Vergara⁷, Mukesh Sharma Paudel⁸, Rupa Banerjee⁹, Ida Hilmi¹⁰, Raja Affendi Raja Ali¹¹, Shu Chen Wei¹², Ka Kei Ng¹³, Mansour Altuwaijri¹⁴, Paul Kelly¹⁵, Jesus K Yamamoto-Furusho¹⁶, Paulo Gustavo Kotze¹⁷, Vineet Ahuja¹⁸, Vui Heng Chong¹⁹, Hang Viet Dao²⁰, Yvonne Abbey²¹, Jessica Y L Ching¹, Agnes Ho¹, Alicia K W Chan¹, Charles N Bernstein²², Richard B Gearry²³, Maria Abreu²⁴, David T Rubin²⁵, Iris Dotan²⁶, Lindsay Hracs²⁷, Gilaad G Kaplan²⁷, Siew C Ng²⁸; GIVES-21 Consortium

Collaborators, Affiliations

Collaborators

GIVES-21 Consortium:
Yan Tao, Jiamei Rong, Xiaocui Chen, Huixian Song, Chan Zhou, Yanju Mu, Wenjuan Wei, Xinyu Bai, Satimai Aniwan, Taya Kitiyakara, Kamin Harinwan, Chalermrat Bunchorntavakul, Karjpong Techathuvanan, Phuripong Kijdamrongthum, Tanita Suttichaimongkol, Panu Wetwittayakhlang, Marcellus Simadibrata, Ari Fahrial Syam, Deka Larasati, Tjahjadi Robert Tedjasaputra, Arlyando Hezron Saragih, Hendra Koncoro, Aizhan Kanabayeva, Nazira Kongyrbayeva, Assem Kurmangaliyeva, Yelena Laryushina, Toktarova Perizat, Ayupova Venera, Kaliyakparova Aidana, Ignacio Toscani, Luciana Nicoloff, Marie Howe, Xin Hui Khoo, Wong Choon Heng, Harjinder Singh, Andrew Chua, Khong Wai Hong, Meng-Tzu Weng, Wei-Chen Lin, Hsi-Chang Lee, Chun-Chao Chang, Chun-Chi Lin, Puo Hsien Le, Tien-Yu Huang, Cheuk-Kay Sun, Hsing-Jung Yeh, Yu Hon Ho, Bashaar AlIbrahim, Mohammed Alahmari, Phoebe Hodges, Bright Nsokolo, Yaw Awuku, Michael Li, Kam Hon Chan, Yip Wai Man, Thomas Wong Yun-Sze, Alex Fong

Affiliations

¹ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
² The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
³ Siriraj Hospital, Bangkok, Thailand.
⁴ University of Indonesia, Depok, Indonesia.
⁵ Research Institute of Cardiology and Internal Diseases, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
⁶ Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina.
⁷ CASMU, Las Piedras, Uruguay.
⁸ National Academy of Medical Sciences, Kathmandu, Nepal.
⁹ Asian Institute of Gastroenterology, Hyderabad, India.
¹⁰ University of Malaya, Kuala Lumpur, Malaysia.
¹¹ The National University of Malaysia, Bangi, Malaysia.
¹² National Taiwan University Hospital, Taipei, Taiwan.
¹³ Conde S. Januário Hospital, Macao SAR, China.
¹⁴ Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
¹⁵ Tropical Gastroenterology & Nutrition Group, University of Zambia School of Medicine, Lusaka, Zambia.
¹⁶ Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirá, Mexico City, Mexico.
¹⁷ Pontifícia Universidade Católica Do Paraná (PUCPR), Curitiba, Brazil.
¹⁸ All India Institute of Medical Sciences, Asian Institute of Gastroenterology, Hyderabad, India.
¹⁹ RIPAS Hospital, Bandar Seri Begawan, Brunei Darussalam.
²⁰ Hanoi Medical University, Hanoi, Vietnam.
²¹ Euracare Hospital, Accra, Ghana.
²² University of Manitoba IBD Clinical and Research Center, Winnipeg, MB, Canada.
²³ Department of Medicine, University of Otago, Christchurch, New Zealand.
²⁴ Department of Medicine, University of Miami Miller School of Medicine, Florida, USA.
²⁵ Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.
²⁶ Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
²⁷ Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
²⁸ Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China. siewchienng@cuhk.edu.hk.

PMID: 37231405
PMCID: PMC10209572
DOI: 10.1186/s12874-023-01944-2

Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21^st century (GIVES-21)

Joyce W Y Mak et al. BMC Med Res Methodol. 2023.

. 2023 May 25;23(1):129.

doi: 10.1186/s12874-023-01944-2.

Authors

Collaborators

GIVES-21 Consortium:
Yan Tao, Jiamei Rong, Xiaocui Chen, Huixian Song, Chan Zhou, Yanju Mu, Wenjuan Wei, Xinyu Bai, Satimai Aniwan, Taya Kitiyakara, Kamin Harinwan, Chalermrat Bunchorntavakul, Karjpong Techathuvanan, Phuripong Kijdamrongthum, Tanita Suttichaimongkol, Panu Wetwittayakhlang, Marcellus Simadibrata, Ari Fahrial Syam, Deka Larasati, Tjahjadi Robert Tedjasaputra, Arlyando Hezron Saragih, Hendra Koncoro, Aizhan Kanabayeva, Nazira Kongyrbayeva, Assem Kurmangaliyeva, Yelena Laryushina, Toktarova Perizat, Ayupova Venera, Kaliyakparova Aidana, Ignacio Toscani, Luciana Nicoloff, Marie Howe, Xin Hui Khoo, Wong Choon Heng, Harjinder Singh, Andrew Chua, Khong Wai Hong, Meng-Tzu Weng, Wei-Chen Lin, Hsi-Chang Lee, Chun-Chao Chang, Chun-Chi Lin, Puo Hsien Le, Tien-Yu Huang, Cheuk-Kay Sun, Hsing-Jung Yeh, Yu Hon Ho, Bashaar AlIbrahim, Mohammed Alahmari, Phoebe Hodges, Bright Nsokolo, Yaw Awuku, Michael Li, Kam Hon Chan, Yip Wai Man, Thomas Wong Yun-Sze, Alex Fong

Affiliations

¹ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
² The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
³ Siriraj Hospital, Bangkok, Thailand.
⁴ University of Indonesia, Depok, Indonesia.
⁵ Research Institute of Cardiology and Internal Diseases, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
⁶ Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina.
⁷ CASMU, Las Piedras, Uruguay.
⁸ National Academy of Medical Sciences, Kathmandu, Nepal.
⁹ Asian Institute of Gastroenterology, Hyderabad, India.
¹⁰ University of Malaya, Kuala Lumpur, Malaysia.
¹¹ The National University of Malaysia, Bangi, Malaysia.
¹² National Taiwan University Hospital, Taipei, Taiwan.
¹³ Conde S. Januário Hospital, Macao SAR, China.
¹⁴ Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
¹⁵ Tropical Gastroenterology & Nutrition Group, University of Zambia School of Medicine, Lusaka, Zambia.
¹⁶ Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirá, Mexico City, Mexico.
¹⁷ Pontifícia Universidade Católica Do Paraná (PUCPR), Curitiba, Brazil.
¹⁸ All India Institute of Medical Sciences, Asian Institute of Gastroenterology, Hyderabad, India.
¹⁹ RIPAS Hospital, Bandar Seri Begawan, Brunei Darussalam.
²⁰ Hanoi Medical University, Hanoi, Vietnam.
²¹ Euracare Hospital, Accra, Ghana.
²² University of Manitoba IBD Clinical and Research Center, Winnipeg, MB, Canada.
²³ Department of Medicine, University of Otago, Christchurch, New Zealand.
²⁴ Department of Medicine, University of Miami Miller School of Medicine, Florida, USA.
²⁵ Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA.
²⁶ Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
²⁷ Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
²⁸ Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China. siewchienng@cuhk.edu.hk.

PMID: 37231405
PMCID: PMC10209572
DOI: 10.1186/s12874-023-01944-2

Abstract

Background: There is a rapid increase in the incidence of inflammatory bowel diseases (IBD) in newly industrialized countries, yet epidemiological data is incomplete. We herein report the methodology adopted to study the incidence of IBD in newly industrialized countries and to evaluate the effect of environmental factors including diet on IBD development.

Methods: Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) is a population-based cohort of newly diagnosed persons with Crohn's disease and ulcerative colitis in Asia, Africa, and Latin America to be followed prospectively for 12 months. New cases were ascertained from multiple sources and were entered into a secured online system. Cases were confirmed using standard diagnostic criteria. In addition, endoscopy, pathology and pharmacy records from each local site were searched to ensure completeness of case capture. Validated environmental and dietary questionnaires were used to determine exposure in incident cases prior to diagnosis.

Results: Through November 2022, 106 hospitals from 24 regions (16 Asia; 6 Latin America; 2 Africa) have joined the GIVES-21 Consortium. To date, over 290 incident cases have been reported. All patients have demographic data, clinical disease characteristics, and disease course data including healthcare utilization, medication history and environmental and dietary exposures data collected. We have established a comprehensive platform and infrastructure required to examine disease incidence, risk factors and disease course of IBD in the real-world setting.

Conclusions: The GIVES-21 consortium offers a unique opportunity to investigate the epidemiology of IBD and explores new clinical research questions on the association between environmental and dietary factors and IBD development in newly industrialized countries.

Keywords: Diet; Environmental; Incidence; Prevalence.

PubMed Disclaimer

Conflict of interest statement

Dr. Ng has received honoraria for speaking or consultancy for Janssen, Abbvie, Takeda, Ferring, Tilotts, Menarini, Pfizer. She has received research support from Olympus, Ferring, Janssen and Abbvie.

Dr. Kaplan has received honoraria for speaking or consultancy from AbbVie, Janssen, Pfizer,

91 Amgen, and Takeda. He has received research support from Ferring, Janssen, AbbVie, Glaxo Smith Kline, Merck, and Shire. He has been a consultant for Gilead. He shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT/CA2018/051098. 7 Sept. 2018.

Dr. Bernstein is supported by the Bingham Chair in Gastroenterology. Dr. Bernstein has served on advisory Boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Roche Canada, JAMP Pharmaceuticals Canada, Janssen Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; Consultant for Mylan Pharmaceuticals and Takeda; Educational grants from Abbvie Canada, Bristol Myers Squibb Canada \, Pfizer Canada, Takeda Canada, and Janssen Canada. Speaker’s panel for Abbvie Canada, Janssen Canada, Pfizer Canada, and Takeda Canada. Received research funding from Abbvie Canada and, Amgen Canada, Sandoz Canada, Takeda Canada, Pfizer Canada.

Dr. Kotze has received speaking and consultancy honorarium from Pfizer, Janssen, Takeda, Abbvie and Novartis. He also received scientific grants from Takeda and Pfizer

Dr. Gearry has received honoraria, consultancy, or research grants from AbbVie, Janssen, Celltrion, Takeda, Ferring and Zespri.

Dr. Yamamoto-Furusho has consulted or served on advisory boards for: AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Ferring pharmaceutical, Janssen, Pfizer and Takeda; Teaching, lecturing, or speaking: Abbvie, Carnot, Celltrion, Schering-Plough, Falk foundation, Ferring, Janssen, MSD, Pfizer, Takeda, UCB, Grants/Research Support: Shire, Bristol Myers, Celgene, Takeda.

Dr. Shu Chen Wei has consulted or served on advisory boards for: AbbVie, Celltrion, Ferring.

Pharmaceuticals Inc., Gilead, Janssen, Pfizer, Takeda, and Tanabe and receives lecture fees from AbbVie, Bristol Myers Squibb, Celltrion, Excelsior Biopharma Inc., Ferring Pharmaceuticals Inc., Janssen, Takeda, Tanabe.

Dr. Paulo G. Kotze has received speaking and consultancy honorarium from Pfizer, Janssen, Takeda, AbbVie, and Novartis, and also has received scientific grants from Takeda and Pfizer.

Dr. Maria T. Abreu has consulted or served on advisory boards or as a consultant for AbbVie Inc, Arena Pharmaceuticals, Bristol Myers Squibb, Celsius, Eli Lilly Pharmaceuticals, Gilead, Helmsley Charitable Trust, Janssen, Microba, Pfizer, Prometheus Biosciences, UCB Biopharma, WebMD Global LLC and has served as a speaker for Alimentiv, Janssen, Prime CME, and Takeda Pharmaceuticals.

Dr. David Rubin has received grant support from Takeda, and has served as a consultant for Abbvie, Altrubio, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Chronicles, Corp/Syneos, ClostraBio, Connect BioPharma, Eco R1, Genentech/Roche, Gilead Sciences, Iterative Health, Janssen Pharmaceuticals, Kaleido Biosciences, Lilly, Pfizer, Prometheus Biosciences, Reistone, Seres Therapeutics, Takeda, Target RWE, and Trellus Health.

Dr. Iris Dotan has received grant support from BMS and Altman Research and has served as a consultant/advisor/speaker to Abbvie, Abbott, Athos, Arena, BMS/Celgene, Celltrion, Cambridge Healthcare, Eli-Lilly, Falk Pharma, Food Industries Organization, Gilead, Galapagos, Genentech/Roche, Iterative Scopes, Integra Holdings, Janssen, Neopharm, Pfizer, Rafa Laboratories, Sublimity, Sangamo, Takeda, Wilbio, Dr. Panu Wetwittayakhlang M.D. has been a speaker and/or advisory board member: Takeda, Pfizer, Janssen, Ferring, A. Menerini, and MSD.

No conflict of interests for other authors.

Cited by

Integrating Proteomics into Personalized Medicine for Inflammatory Bowel Disease-Reality or Challenge?
Minea H, Singeap AM, Minea M, Juncu S, Chiriac SA, Sfarti CV, Stanciu C, Trifan A. Minea H, et al. Int J Mol Sci. 2025 May 22;26(11):4993. doi: 10.3390/ijms26114993. Int J Mol Sci. 2025. PMID: 40507799 Free PMC article. Review.
Vascular endothelial growth factor in inflammatory bowel disease: A systematic review and meta-analysis.
Zoroddu S, Di Lorenzo B, Paliogiannis P, Mangoni AA, Carru C, Zinellu A. Zoroddu S, et al. Eur J Clin Invest. 2025 Mar;55(3):e14361. doi: 10.1111/eci.14361. Epub 2024 Nov 15. Eur J Clin Invest. 2025. PMID: 39545600 Free PMC article.
Targeted oral delivery of microencapsulated TNF-α siRNA in an experimental model of colitis.
Stalder T, Moulari B, Cornu R, Chatelain J, Koenig N, Hassan A, Chretien C, Boidot R, Richard C, Pellequer Y, Jurin F, Pierre H, Martin H, Béduneau A. Stalder T, et al. Drug Deliv Transl Res. 2025 Aug 6. doi: 10.1007/s13346-025-01936-3. Online ahead of print. Drug Deliv Transl Res. 2025. PMID: 40770585
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response.
Solitano V, Bernstein CN, Dotan I, Dignass A, Domilici R, Dubinsky MC, Gearry RB, Hart A, Kaplan GG, Ma C, Magro F, Mak JWY, Ng SC, Panaccione R, Raja S, Rubin DT, Siegel CA, Jairath V, Peyrin-Biroulet L, Danese S. Solitano V, et al. Nat Rev Gastroenterol Hepatol. 2025 Jun;22(6):438-452. doi: 10.1038/s41575-025-01063-x. Epub 2025 Apr 22. Nat Rev Gastroenterol Hepatol. 2025. PMID: 40263433 Review.
Protective effect of zinc oxide nanoparticles synthesized using Cassia alata for DSS-induced ulcerative colitis in mice model.
Govindarasu M, Vaiyapuri M, Kim JC. Govindarasu M, et al. Bioprocess Biosyst Eng. 2024 Aug;47(8):1393-1407. doi: 10.1007/s00449-024-03047-8. Epub 2024 Jun 28. Bioprocess Biosyst Eng. 2024. PMID: 38942827

See all "Cited by" articles

References

1. Hammer T, Langholz E. The epidemiology of inflammatory bowel disease: balance between East and West? A narrative review. Digestive Medicine Research 2020;3. https://cdn.amegroups.cn/journals/ales/files/journals/34/articles/6855/p....
1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
1. Coward S, Clement F, Benchimol EI, et al. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology. 2019;156(1345–1353):e4. - PubMed
1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54 e42. doi: 10.1053/j.gastro.2011.10.001. - DOI - PubMed
1. Kotze PG, Underwood FE, Damiao A, et al. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:304–312. doi: 10.1016/j.cgh.2019.06.030. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

PJT-162393/CIHR/Canada

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Hammer T, Langholz E. The epidemiology of inflammatory bowel disease: balance between East and West? A narrative review. Digestive Medicine Research 2020;3. https://cdn.amegroups.cn/journals/ales/files/journals/34/articles/6855/p....

[2] Hammer T, Langholz E. The epidemiology of inflammatory bowel disease: balance between East and West? A narrative review. Digestive Medicine Research 2020;3. https://cdn.amegroups.cn/journals/ales/files/journals/34/articles/6855/p....

[3] Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed

[4] Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed

[5] Coward S, Clement F, Benchimol EI, et al. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology. 2019;156(1345–1353):e4. - PubMed

[6] Coward S, Clement F, Benchimol EI, et al. Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology. 2019;156(1345–1353):e4. - PubMed

[7] Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54 e42. doi: 10.1053/j.gastro.2011.10.001. - DOI - PubMed

[8] Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54 e42. doi: 10.1053/j.gastro.2011.10.001. - DOI - PubMed

[9] Kotze PG, Underwood FE, Damiao A, et al. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:304–312. doi: 10.1016/j.cgh.2019.06.030. - DOI - PubMed

[10] Kotze PG, Underwood FE, Damiao A, et al. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:304–312. doi: 10.1016/j.cgh.2019.06.030. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21^st century (GIVES-21)

Collaborators

Affiliations

Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21^st century (GIVES-21)

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical